KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Gains from Sales and Divestitures (2016 - 2022)

Medpace Holdings (MEDP) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $82000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Gains from Sales and Divestitures changed N/A year-over-year to $82000.0, compared with a TTM value of $82000.0 through Jun 2022, changed N/A, and an annual FY2021 reading of $119000.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $82000.0 for Q2 2022 at Medpace Holdings, roughly flat from $82000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $119000.0 in Q3 2021 and bottomed at $29629.0 in Q4 2018.
  • Average Gains from Sales and Divestitures over 3 years is $86325.8, with a median of $82000.0 recorded in 2022.
  • Peak annual rise in Gains from Sales and Divestitures hit 0.0% in 2018, while the deepest fall reached 0.0% in 2018.
  • Year by year, Gains from Sales and Divestitures stood at $29629.0 in 2018, then soared by 301.63% to $119000.0 in 2021, then plummeted by 31.09% to $82000.0 in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for MEDP at $82000.0 in Q2 2022, $82000.0 in Q1 2022, and $119000.0 in Q4 2021.